Lapatinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lapatinib: From HER2-Positive Breast Cancer to Dermatofibrosarcoma Protuberans
One-Sentence Summary
Lapatinib (Tykerb/Tyverb) is a dual tyrosine kinase inhibitor targeting EGFR and HER2, originally approved for the treatment of HER2-positive metastatic breast cancer in combination with other agents. The TxGNN model predicts it may be effective for Dermatofibrosarcoma Protuberans (DFSP), with a prediction confidence of 99.30% — however, no clinical trials or supporting literature currently exist for this combination, and the mechanistic rationale is limited.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HER2-positive metastatic breast cancer (not registered in Taiwan) |
| Predicted New Indication | Dermatofibrosarcoma Protuberans (DFSP) |
| TxGNN Prediction Score | 99.30% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacology, Lapatinib is a small-molecule inhibitor that reversibly binds the ATP-binding pocket of both EGFR (HER1/ErbB1) and HER2 (ErbB2) tyrosine kinases. This dual blockade suppresses downstream PI3K/AKT and RAS/MAPK signaling cascades — pathways that are critical for proliferation and survival in HER2-amplified tumors. Its oral bioavailability and CNS penetration distinguish it from antibody-based HER2 therapies such as trastuzumab.
Dermatofibrosarcoma Protuberans (DFSP) is a rare dermal sarcoma characterized by the COL1A1-PDGFB gene fusion, which drives constitutive PDGFR (platelet-derived growth factor receptor) signaling. The established targeted therapy for advanced DFSP is Imatinib, a PDGFR inhibitor — not an EGFR/HER2 inhibitor. EGFR overexpression or HER2 amplification has not been documented as a key oncogenic mechanism in DFSP, making the mechanistic basis for Lapatinib in this setting comparatively weak.
The TxGNN model’s high confidence score (99.30%) most likely reflects network-level structural similarity within the receptor tyrosine kinase inhibitor drug class and overlapping graph topology, rather than a direct mechanistic match with the primary DFSP driver. Notably, among all 10 predicted indications reviewed, the most scientifically coherent signal is for Plasmodium falciparum malaria (Rank 8, L4 evidence), where in vitro studies directly demonstrate haemozoin inhibition — a mechanism with substantially stronger scientific support than the DFSP prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No marketing authorization records are present in the current evidence pack (market status: not marketed, 0 registered licenses). This may reflect a data gap rather than confirmed absence from the EU market, as Lapatinib is known internationally under the brand name Tyverb. Verification against the EMA product database is recommended.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — Dual EGFR/HER2 tyrosine kinase inhibitor (TKI); not a conventional cytotoxic agent |
| Myelosuppression Risk | Low to moderate (neutropenia and thrombocytopenia are reported but less frequent than with traditional chemotherapy) |
| Emetogenicity Classification | Low |
| Monitoring Items | Liver function tests (LFTs; hepatotoxicity risk), left ventricular ejection fraction (LVEF assessment prior to and during treatment), CBC with differential, QTc interval (cardiac monitoring), skin toxicity evaluation (rash, hand-foot syndrome) |
| Handling Protection | Classified as a hazardous drug on the NIOSH list; standard cytotoxic-safe handling precautions are recommended per institutional pharmacy guidelines |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite the TxGNN model’s high algorithmic confidence (99.30%), there is no clinical trial evidence and no supporting literature for Lapatinib in DFSP, and the primary oncogenic driver of DFSP — PDGFR activation via the COL1A1-PDGFB fusion — is mechanistically distinct from Lapatinib’s EGFR/HER2 targets, leaving no established scientific basis for this repurposing direction at this time.
To proceed, the following is needed:
- Evidence of EGFR or HER2 overexpression in DFSP tumor samples (IHC, FISH, or transcriptomic analysis) to establish a target-disease link
- Preclinical sensitivity testing of Lapatinib in DFSP cell lines or patient-derived xenograft models
- Full MOA data retrieval from DrugBank (data gap DG002) to strengthen mechanistic rationale analysis
- TFDA SmPC retrieval and parsing (data gap DG001, blocking severity) to enable safety pre-screening
- Priority redirection: Consider advancing the Plasmodium falciparum malaria signal (Rank 8, L4 evidence; 3 supporting publications including direct haemozoin inhibition data, PMID 32235391) as a higher-priority repurposing candidate for focused investigation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.